Spyre Therapeutics logo

Spyre Therapeutics

SYRE | NASDAQ
Chart Builder DCF Calculator
$99.37
-$4.63 (-4.45%)
At close: Nov 16, 2026, 4:00 PM ET
$99.37
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.45%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
53.4
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #213/1021 (Top 21%)

Key Statistics

Market Data

Market Cap $9.44B
1D Range
98.82 106.20
52W Range
23.47 109.00

Valuation (TTM)

PE -36.27
PB 8.97
EV/EBITDA -30.93

Valuation (NTM)

Forward PE N/A
Forward PEG -0.75
Price Target $120.50
Loading financial charts...

Profile

Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among ...

Sector Healthcare
Industry Biotechnology
Employees 125
IPO Date Apr 7, 2016
Fiscal Year January - December

Latest News

Spyre Therapeutics, Inc. (SYRE) Presents at UBS Global Biopharma Conference 2026 Transcript

14 hours ago · seekingalpha.com

Spyre Therapeutics, Inc. (SYRE) Presents at UBS Global Biopharma Conference 2026 Transcript
Spyre Therapeutics Announces Grants of Inducement Awards

10 days ago · globenewswire.com

Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

13 days ago · globenewswire.com

Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

30 days ago · globenewswire.com

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

1 month ago · globenewswire.com

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

1 month ago · globenewswire.com

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

2 months ago · seekingalpha.com

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study

2 months ago · zacks.com

Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
Spyre Therapeutics to Participate in Upcoming September Investor Conferences

2 months ago · globenewswire.com

Spyre Therapeutics to Participate in Upcoming September Investor Conferences
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?

2 months ago · zacks.com

Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?

Analyst Summary

# of Analysts
13
Consensus
Buy
Price Target
$120.50
Upside
+21.26%
Buy (12)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.